The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study.
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); BioTheryX (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CicloMed (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Incyte (Inst); Novartis (Inst); TG Therapeutics (Inst); Vincerx Pharma (Inst)
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Incyte; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
Eric B. Haura
Consulting or Advisory Role - Amgen; Ellipses Pharma; Janssen; Janssen; Janssen Research & Development; Revolution Medicines
Research Funding - AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Protein-Protein Interactions as Biomarkers Patent
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Elevation Oncology; Turning Point Therapeutics
Honoraria - ARIAD/Takeda; BeiGene; Caris Life Sciences; Daiichi Sankyo; Dava Oncology; Johnson & Johnson/Janssen; Lilly; Pfizer
Consulting or Advisory Role - BeiGene; Daiichi Sankyo; Elevation Oncology; Janssen; Lilly; Pfizer; Takeda
Speakers' Bureau - Caris Life Sciences
Research Funding - ARIAD (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Anna Capasso
No Relationships to Disclose
 
Pamela N. Munster
Leadership - Alessa Therapeutics; EpiAxis Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; OnKure
Honoraria - Alkermes; AstraZeneca/Merck; Athenex; GlaxoSmithKline; Olema Pharmaceuticals
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; BeiGene; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Immune Design (Inst); Merck (Inst); Novartis (Inst); oncosec (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Tempest Therapeutics (Inst); Tesaro/GSK (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
 
Hidenori Kitai
No Relationships to Disclose
 
Zhican Wang
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Josie Hayes
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Lin Tao
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Sofia Wong
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Yu Chi Yang
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
Patents, Royalties, Other Intellectual Property - Revolution Medicines
 
Jingjing Jiang
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
Patents, Royalties, Other Intellectual Property - Revolution Medicines
 
Bojena Bitman
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Mallika Singh
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
W. Clay Gustafson
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Neal Rosen
Stock and Other Ownership Interests - BeiGene; Fortress Biotech; Kura Oncology; Zai Lab
Consulting or Advisory Role - Array BioPharma/Pfizer; AstraZeneca/MedImmune; BeiGene; Chugai Pharma; Ribon Therapeutics; Tarveda Therapeutics; Zai Lab
Research Funding - AstraZeneca/MedImmune; Boehringer Ingelheim; Revolution Medicines
 
Alison M. Schram
Consulting or Advisory Role - Mersana
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Northern Biologics (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst)